Interested in the ground-breaking use of psychedelic medicines in therapy for conditions such as post-traumatic stress disorder, depression, anxiety and addiction?
Mind Medicine Australia is presenting its inaugural Summit on Psychedelic Medicines for Mental Health, to be held online on 19 and 20 November 2021.
Mind Medicine Australia is a registered charity, focused on the clinical application of psychedelic medicines to treat mental illness in Australia.
In the past decade, there have been more than 120 psychedelic medicine trials worldwide, focusing on depression, anxiety, addiction, and PTSD.
Up to 80% of patients in these trials shown significant improvement after just 2-3 small medicinal doses of MDMA or psilocybin, in tandem with psychotherapy. Trials for psychedelic-assisted psychotherapy for dementia and anorexia patients have yielded similar results.
PACFA is excited to partner with Mind Medicine Australia for its inaugural summit, which will feature a mixture of international and national keynote speakers, master classes, panel conversations, and Q & A sessions. PACFA members are also invited to an introductory workshop for therapists and health professionals on psychedelic therapies to be held online on 17 and 18 November, 2021, just before the summit.
Leading international speakers confirmed for the 2-day summit and Mind Medicine Australia Ambassadors include:
• Professor David Nutt (UK) Head of Neuropsychopharmacology at Imperial College London and lead advisor on psilocybin assisted therapy for treatment-resistant depression
• Dr Gabor Maté (Canada) renowned trauma and addiction physician
• Johann Hari (UK) journalist and bestselling author
• Dr Ben Sessa (UK) psychiatrist, researcher and writer and currently leading the Imperial College trials on using MDMA therapy for alcohol dependence
• Dr Robin Carhart-Harris (UK) Head of the Centre for Psychedelic Research, Imperial College London
• Francoise Bourzat (USA) Counselor and Author
Key themes will include:
● Ethical, legal, and implementation frameworks for psychedelic treatments
● The current state of mental health in Australia and existing treatments
● Clinical outcomes of psychedelic treatment for mental illness
● Therapeutic mechanisms, enhancing effectiveness and minimising risks of psychedelic treatments
● The way forwards for Australia: Challenges and preparation towards creating a new paradigm
● Creating the future: What the psychedelic industry will look like 5 years out?
Psilocybin and MDMA assisted therapies have been granted 'breakthrough therapy' status by the FDA in the USA due to current promising research in the treatment of depression and PTSD
PACFA members are eligible for a 10% discount on tickets to both the summit and workshop. Please use the code MMA2021 to apply the discount. You can purchase tickets here.
Read more about Mind Medicine Australia and the summit.
